Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Peripheral Nervous System Diseases × eribulin × Breast × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 103 Triple Negative Breast Neoplasms 23 Neoplasm Metastasis 14 Ovarian Neoplasms 4 Brain Neoplasms 4 Neoplasms 3 Inflammatory Breast Neoplasms 3 Sarcoma 2 Recurrence 2 Prostatic Neoplasms 2 HER2-negative Breast Cancer 2 Carcinoma 2 Peripheral Nervous System Diseases 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Neurotoxicity Syndromes 1 Neoplastic Cells, Circulating 1 Neoplasm, Residual 1 Meningeal Neoplasms 1 Meningeal Carcinomatosis 1 Ketosis 1 HR+HER2- Breast Cancer 1 HR Positive HER2 Negative Advanced Breast Cancer 1 HER2-negative Metastatic Breast Cancer 1 HER2-low Breast Cancer 1 HER-2 Positive Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Drug-Related Side Effects and Adverse Reactions 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 3 Glutamine 2 Fatty Acids, Omega-3 2 Cryotherapy 2 Acupuncture Therapy 2 eribulin 1 Yoga 1 Vitamin D 1 Vitamin B 6 1 Vitamin B 12 1 Thioctic Acid 1 Taxoids 1 Sugars 1 Sodium Chloride 1 Saline Solution 1 Physical Therapy Modalities 1 Pentoxifylline 1 Omacor 1 Minocycline 1 Metformin 1 Massage 1 Magnetic Resonance Spectroscopy 1 Losartan 1 Lidocaine 1 Hydroxychloroquine 1 Fumigant 93 1 Fish Oils 1 Etoricoxib 1 Duloxetine Hydrochloride 1 Diffusion Tensor Imaging 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03027245 2022-07-13

IRENE

Eisai Inc.

Breast Neoplasms, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡